Avid Bioservices: ESTEVE CDMO Expands with Regis Technologies Acquisition to Enhance Service Capabilities
- ESTEVE CDMO acquires Regis Technologies, enhancing its capabilities in active pharmaceutical ingredient (API) services and manufacturing.
- The acquisition adds skilled professionals and expands ESTEVE’s service offerings, including process development and cGMP API manufacturing.
- ESTEVE aims to strengthen its global footprint and early-stage development capabilities through advanced technologies post-acquisition.
Esteve CDMO Expands Capabilities with Regis Technologies Acquisition
In a significant move within the contract development and manufacturing organization (CDMO) sector, ESTEVE CDMO announces its acquisition of Regis Technologies, a well-established player based in Chicago. With over 65 years of experience in active pharmaceutical ingredient (API) services, Regis Technologies complements ESTEVE's existing portfolio, allowing for a broader range of services from pre-clinical development to commercial manufacturing. This strategic acquisition not only enhances ESTEVE's capabilities in small-molecule APIs but also strengthens its market position in the United States.
The integration of Regis Technologies introduces a suite of offerings that elevate ESTEVE's service capabilities. These include process research and development, analytical and stability testing, and cGMP API manufacturing. With the addition of approximately 70 skilled professionals from Regis, ESTEVE is poised to bolster its workforce and enhance the efficiency of its operations. Joan Petit, Chief Industrial Operations Officer of ESTEVE, underscores the significance of this acquisition in enriching their service offerings for pharmaceutical innovators. This strategic alignment aims to streamline processes and enhance support for clients in all phases of drug development.
Furthermore, Andrea Oro, Global Head of Commercial Operations and Strategy at ESTEVE, highlights the acquisition's role in expanding the company's global manufacturing footprint and enhancing early-stage development capabilities. This expansion aligns with ESTEVE’s commitment to leveraging advanced technologies, such as Spray Drying and high-potency API manufacturing, to deliver high-quality products to clients. Scott Aladeen, President and CEO of Regis Technologies, expresses excitement about joining ESTEVE, emphasizing the shared mission of providing long-term value to customers in an industry that demands innovation and excellence.
In light of this acquisition, the CDMO industry continues to witness consolidation as companies seek to enhance their service offerings and operational efficiencies. ESTEVE's decision to acquire Regis Technologies reflects a broader trend where firms aim to combine expertise and resources to meet the evolving needs of pharmaceutical developers. As the industry moves toward more integrated service models, the partnership between ESTEVE and Regis Technologies may set a benchmark for future collaborations in the sector.
With a legacy dating back to 1929, ESTEVE maintains a strong international presence across several European countries and the United States, positioning itself as a key player in the pharmaceutical industry. By integrating Regis Technologies into its operational framework, ESTEVE not only enhances its capabilities but also reaffirms its commitment to improving lives through innovative treatments and comprehensive CDMO services.
